MIR1302-10: A Drug Target / Disease Biomarker (G100422834)
MIR1302-10: A Drug Target / Disease Biomarker
MIR1302-10 is a protein that is expressed in the human placenta and has been shown to play a role in pregnancy complications. It is a member of the immunoglobulin superfamily and is localized to the cell surface. MIR1302-10 has been shown to interact with several other proteins, including PDGF, FGF, and TGF-β.
One of the functions of MIR1302-10 is to regulate the growth and differentiation of cells in the placenta. It has been shown to promote the survival and proliferation of pre-implantation embryos and to inhibit the destruction of pre-implantation embryos by the host immune system.
MIR1302-10 is also involved in the regulation of inflammation in the placenta. It has been shown to dampen the immune response to foreign particles, such as bacteria and viruses, and to protect the placenta from inflammation.
In addition to its role in cell survival and inflammation, MIR1302-10 has also been shown to play a role in the development of certain diseases, such as preterm labor and preterm birth. It has been shown to be expressed in the placenta of pregnant women with preterm labor and to be associated with an increased risk of preterm delivery.
Given its involvement in cell survival and inflammation, MIR1302-10 is a potential drug target or biomarker for the treatment of a variety of diseases, including preterm labor and preterm birth. It is also a good candidate for further study as a potential therapeutic agent for these diseases.
Overall, MIR1302-10 is a protein that has important roles in the development and maintenance of pregnancy and is a potential drug target or biomarker for the treatment of a variety of diseases. Further research is needed to fully understand its function and to develop safe and effective treatments for these diseases.
Protein Name: MicroRNA 1302-10
The "MIR1302-10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1302-10 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913
